Featured Research

from universities, journals, and other organizations

When Our Protective Armor Shows Weakness: Genetic Defect In Skin Cells Leads To Neurodermatitis, Hay Fever And Asthma

Date:
August 4, 2008
Source:
Helmholtz Zentrum Muenchen - German Research Centre for Environmental Health
Summary:
New knowledge points to the fact that a genetically induced lack of filaggrin, a key protein of the skin barrier, plays a decisive role in the origin of allergies. In a large study on more than 3000 school-children scientists found that about 8% of the German population carry variations of the filaggrin gene, which raise the risk to develop atopic dermatitis more than threefold. In addition, these genetic variations predispose to hay fever and asthma in those with atopic dermatitis.

New knowledge points to the fact that a genetically induced lack of filaggrin, a key protein of the skin barrier, plays a decisive role in the origin of allergies.

In a large study on more than 3000 school-children scientists of the Helmholtz Zentrum München and the Technische Universität München found that about 8% of the German population carry variations of the filaggrin gene, which raise the risk to develop atopic dermatitis more than threefold. In addition, these genetic variations predispose to hay fever and asthma in those with atopic dermatitis.

Allergic diseases have increased considerably in the past decades in most industrial countries. A combination of genetic and environmentally related factors is said to be the cause. In recent years, several genes were examined for a role in allergic diseases, and one of them actually turned out to be a key player. This gene encodes filaggrin, an essential protein in the horny layer of the skin. If this protein is reduced or lacking due to a genetic defect, the natural cornification is impeded and the natural barrier function of the skin is limited.

In 2006 filaggrin mutations could be identified as cause of the so-called fish scale disease or ichthyosis vulgaris, and as risk factors for the development of atopic dermatitis, a genetic breakthrough made by the Irish research team around Irwin McLean and Alan Irvine.

In an international collaboration, Dr. Stephan Weidinger from the Technische Universität München and Dr. Thomas Illig from the Helmholtz Zentrum München now investigated 3,000 school children, representing the population as a whole. The study was carried out together with Dr. Michael Kabesch of the Children's Hospital of the Kudwig-Maximilians-University Munich.

The Munich scientists found that almost 8% of the children in Germany suffer from a genetically determined deficiency of filaggrin protein in the skin. These children have a more than threefold increased risk to develop atopic dermatitis. "In general, our results show that mutations in the filaggrin gene are extremely strong risk factors for atopic dermatitis and beyond that for hay fever. In the case of pre-existing eczema they may also cause asthma," explained Weidinger The asthma results were especially surprising, because filaggrin is not present in the respiratory tract, but appears to be of importance in the skin only."A weakened skin barrier function might enable allergens to penetrate more easily and thereby promote the development of allergies.”

In addition, in another recent study on 1600 adults from the KORA cohort (Co-operative Health Research in the Augsburg Region), which represents the German population as a whole, Weidinger and Illig found out that a deficiency of filaggrin protein due to genetic variants also increases the risk for allergic contact eczema, especially of allergic reactions to nickel, which is often found in costume jewelry.

The current results show that the skin plays a crucial role in the development of different allergic diseases. "We are now interested in finding out the precise consequences of filaggrin mutations," declared Illig. "The next thing to do is to examine the metabolic pathway of this important protein. In addition, we want to clarify which molecular mechanisms play a role at the genetic level, but also concerning the protein itself. Then, the final aim, of course, is to find a therapy for patients with atopic diseases," added Illig. "If a lack of filaggrin is such an important factor in allergic diseases, it would be almost conceivable to increase production of this protein or to replace its function in other ways”.


Story Source:

The above story is based on materials provided by Helmholtz Zentrum Muenchen - German Research Centre for Environmental Health. Note: Materials may be edited for content and length.


Cite This Page:

Helmholtz Zentrum Muenchen - German Research Centre for Environmental Health. "When Our Protective Armor Shows Weakness: Genetic Defect In Skin Cells Leads To Neurodermatitis, Hay Fever And Asthma." ScienceDaily. ScienceDaily, 4 August 2008. <www.sciencedaily.com/releases/2008/08/080801074740.htm>.
Helmholtz Zentrum Muenchen - German Research Centre for Environmental Health. (2008, August 4). When Our Protective Armor Shows Weakness: Genetic Defect In Skin Cells Leads To Neurodermatitis, Hay Fever And Asthma. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2008/08/080801074740.htm
Helmholtz Zentrum Muenchen - German Research Centre for Environmental Health. "When Our Protective Armor Shows Weakness: Genetic Defect In Skin Cells Leads To Neurodermatitis, Hay Fever And Asthma." ScienceDaily. www.sciencedaily.com/releases/2008/08/080801074740.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) — Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) — Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) — Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins